Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
8
×
life sciences
national blog main
national top stories
8
×
roche
8
×
san francisco top stories
biotech
boston blog main
boston top stories
san francisco blog main
fda
national
new york top stories
cancer
deals
investing
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
merck
alexion pharmaceuticals
alnylam pharmaceuticals
biogen
blueprint medicines
boston
What
drug
8
×
cancer
fda
medicines
new
roche
roundup
approved
bio
home
intended
medicine
patients
pricing
research
targets
team
advanced
advantages
ahead
ambien
american
annual
approval
arrival
asco
atrophy
attendees
attention
award
bar
biotech
blueprint
brings
camp’s
candidate
cash
caught
causing
chicago
Language
unset
Current search:
roche
×
drug
×
" national top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More